v3.25.2
Unaudited Condensed Consolidated Statements of Changes in Stockholder’s Equity - USD ($)
$ in Thousands
Preferred stock
Series A
Preferred stock
Series B
Common stock
Additional paid-in capital
Accumulated defecit
Total
Balance at Dec. 31, 2023 $ 25,443 $ (24,905) $ 538
Balance (in Shares) at Dec. 31, 2023 6,000 17,305      
Net loss         (3,372) (3,372)
Preferential issue 956 956
Preferential issue (in Shares)     2,245      
Conversion of Debt to Equity 1,181 1,181
Conversion of Debt to Equity (in Shares)     3,008      
Stock based compensation       51   51
Balance at Jun. 30, 2024 27,631 (28,277) (646)
Balance (in Shares) at Jun. 30, 2024 6,000 22,558      
Balance at Mar. 31, 2024 26,256 (26,767) (511)
Balance (in Shares) at Mar. 31, 2024 6,000 18,981      
Net loss         (1,510) (1,510)
Preferential issue 956 956
Preferential issue (in Shares)     2,245      
Conversion of Debt to Equity 394 394
Conversion of Debt to Equity (in Shares)     1,332      
Stock based compensation       25   25
Balance at Jun. 30, 2024 27,631 (28,277) (646)
Balance (in Shares) at Jun. 30, 2024 6,000 22,558      
Balance at Dec. 31, 2024 $ 7,435 21,022 (33,571) (5,114)
Balance (in Shares) at Dec. 31, 2024 6,000 1,600,000 22,759      
Net loss         (3,068) (3,068)
Shares issued for acquisition 88 88
Shares issued for acquisition (in Shares) 14,000 527      
Common stock issued for cash 95 95
Common stock issued for cash (in Shares)     28,183      
Prefunded warrants issued for cash 395 395
Prefunded warrants issued for cash (in Shares) 117,161      
Series B (cashless warrants) $ 11 14,699 14,710
Series B (cashless warrants) (in Shares) 4,262,212      
Expenses relating to funding (1,524) (1,524)
Shares issued for acquisition $ 3 2,997 3,000
Shares issued for acquisition (in Shares)     1,388,041      
Conversion of Debt to Equity 1,191 1,191
Conversion of Debt to Equity (in Shares)     10,559      
Shares issued for acquisition (Contingent Consideration) 400 400
Shares issued for acquisition (Contingent Consideration) (in Shares)     2,387      
Stock based compensation 36 36
Balance at Jun. 30, 2025 $ 7,435 $ 14 39,399 (36,639) 10,209
Balance (in Shares) at Jun. 30, 2025 20,000 1,600,000 5,831,829      
Balance at Mar. 31, 2025 $ 7,435 36,413 (35,271) 8,577
Balance (in Shares) at Mar. 31, 2025 20,000 1,600,000 64,415      
Net loss         (1,368) (1,368)
Prefunded warrants issued for cash [1]
Prefunded warrants issued for cash (in Shares) [1] 117,161      
Series B (cashless warrants) [2] $ 11 (11)
Series B (cashless warrants) (in Shares) [2] 4,262,212      
Shares issued for acquisition [3] $ 3 2,997 3,000
Shares issued for acquisition (in Shares) [3] 1,388,041      
Balance at Jun. 30, 2025 $ 7,435 $ 14 $ 39,399 $ (36,639) $ 10,209
Balance (in Shares) at Jun. 30, 2025 20,000 1,600,000 5,831,829      
[1] 117,161 shares of Common Stock that may be issued on full exercise of the pre-funded warrants issued at $0.42 per share.
[2] Up to 4,360,300   shares of Common Stock that may be issued on exercise of the Series B warrants using the “zero exercise price option”.
[3] On June 16, 2025, Healthcare Triangle, Inc. through its wholly owned subsidiary QuantumNexis Inc. (the “Company”) and Niyama Healthcare, Inc., a Delaware corporation, a provider of Mental Health and Hospital Information Systems technology, across India, Southeast Asia, and Europe (the “Seller”) entered into an Asset Transfer Agreement (the “Agreement”). Pursuant to the Agreement, the Company agreed to a total consideration for the acquisition, which is referred to herein as the “Purchase Price” is $5.7 million which includes: (1) $1.5 million in cash, of which $1.2 million is due on the Closing Date and $300,000 to be paid at the later of the satisfaction of certain withholding requirements or within 120 days of the Closing Date; (2) a number of shares of restricted common stock of the Company equal to $3,000,000 divided by $2.17, issued on the Closing Date; and (3) up to $1.2 million in earn-out payments contingent on first-year financial performance targets to be agreed upon within 90 days of the Closing Date.